- <Centre d'Information et de documentation du CRA Rhône-Alpes
- CRA
- Informations pratiques
-
Adresse
Centre d'information et de documentation
Horaires
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexLundi au Vendredi
Contact
9h00-12h00 13h30-16h00Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Adresse
Détail de l'auteur
Auteur Jessica F. DOUGLAS |
Documents disponibles écrits par cet auteur (1)
Faire une suggestion Affiner la recherche
Brief Report: Retrospective Case Series of Oxcarbazepine for Irritability/Agitation Symptoms in Autism Spectrum Disorder / Jessica F. DOUGLAS in Journal of Autism and Developmental Disorders, 43-5 (May 2013)
[article]
Titre : Brief Report: Retrospective Case Series of Oxcarbazepine for Irritability/Agitation Symptoms in Autism Spectrum Disorder Type de document : Texte imprimé et/ou numérique Auteurs : Jessica F. DOUGLAS, Auteur ; Kevin B. SANDERS, Auteur ; M. Hannah BENNEYWORTH, Auteur ; Jessica L. SMITH, Auteur ; Virginia M. DEJEAN, Auteur ; Susan G. MCGREW, Auteur ; Jeremy VEENSTRA-VANDERWEELE, Auteur Article en page(s) : p.1243-1247 Langues : Anglais (eng) Mots-clés : Antiepileptic Anticonvulsant Mood stabilizer Sodium channel Pervasive developmental disorder Index. décimale : PER Périodiques Résumé : We examined response to oxcarbazepine prescribed for irritability/agitation symptoms in a retrospective case series of 30 patients with Autism Spectrum Disorder (ASD). The average patient was 12.0 years old (range 5–21) and taking two other psychotropic medications (range 0–4). Fourteen patients (47 %) had a clinical global impression of improvement score of ‘much improved’ during treatment. Ten patients (33 %) showed an improvement on their clinical global impression of severity score. Seven patients (23 %) had a clinically significant adverse event or side effect leading to oxcarbazepine discontinuation. Without a placebo group, it is not possible to evaluate whether oxcarbazepine provides benefit for irritability/agitation symptoms in ASD. The high rate of adverse events suggests its use should be accompanied by caution. En ligne : http://dx.doi.org/10.1007/s10803-012-1661-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=195
in Journal of Autism and Developmental Disorders > 43-5 (May 2013) . - p.1243-1247[article] Brief Report: Retrospective Case Series of Oxcarbazepine for Irritability/Agitation Symptoms in Autism Spectrum Disorder [Texte imprimé et/ou numérique] / Jessica F. DOUGLAS, Auteur ; Kevin B. SANDERS, Auteur ; M. Hannah BENNEYWORTH, Auteur ; Jessica L. SMITH, Auteur ; Virginia M. DEJEAN, Auteur ; Susan G. MCGREW, Auteur ; Jeremy VEENSTRA-VANDERWEELE, Auteur . - p.1243-1247.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 43-5 (May 2013) . - p.1243-1247
Mots-clés : Antiepileptic Anticonvulsant Mood stabilizer Sodium channel Pervasive developmental disorder Index. décimale : PER Périodiques Résumé : We examined response to oxcarbazepine prescribed for irritability/agitation symptoms in a retrospective case series of 30 patients with Autism Spectrum Disorder (ASD). The average patient was 12.0 years old (range 5–21) and taking two other psychotropic medications (range 0–4). Fourteen patients (47 %) had a clinical global impression of improvement score of ‘much improved’ during treatment. Ten patients (33 %) showed an improvement on their clinical global impression of severity score. Seven patients (23 %) had a clinically significant adverse event or side effect leading to oxcarbazepine discontinuation. Without a placebo group, it is not possible to evaluate whether oxcarbazepine provides benefit for irritability/agitation symptoms in ASD. The high rate of adverse events suggests its use should be accompanied by caution. En ligne : http://dx.doi.org/10.1007/s10803-012-1661-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=195